Benjamin F. Edwards & Company Inc. Raises Stock Position in Stryker Co. (NYSE:SYK)

Benjamin F. Edwards & Company Inc. increased its holdings in shares of Stryker Co. (NYSE:SYK) by 5.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,193 shares of the medical technology company’s stock after purchasing an additional 861 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Stryker were worth $3,400,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Voloridge Investment Management LLC purchased a new stake in shares of Stryker during the third quarter worth about $4,589,000. Granite Investment Advisors LLC increased its stake in shares of Stryker by 0.7% during the third quarter. Granite Investment Advisors LLC now owns 17,847 shares of the medical technology company’s stock worth $3,860,000 after purchasing an additional 120 shares in the last quarter. Gradient Investments LLC increased its stake in shares of Stryker by 95.4% during the fourth quarter. Gradient Investments LLC now owns 1,135 shares of the medical technology company’s stock worth $238,000 after purchasing an additional 554 shares in the last quarter. Synovus Financial Corp increased its stake in shares of Stryker by 3.0% during the third quarter. Synovus Financial Corp now owns 3,829 shares of the medical technology company’s stock worth $826,000 after purchasing an additional 111 shares in the last quarter. Finally, Bridger Capital Management LLC purchased a new stake in shares of Stryker during the third quarter worth about $90,000. 73.29% of the stock is owned by hedge funds and other institutional investors.

NYSE:SYK opened at $221.54 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 2.58 and a quick ratio of 1.84. The firm has a market capitalization of $82.98 billion, a price-to-earnings ratio of 40.43, a PEG ratio of 2.40 and a beta of 0.74. The company’s 50-day moving average is $212.31 and its two-hundred day moving average is $211.89. Stryker Co. has a 1-year low of $174.84 and a 1-year high of $223.45.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.46 by $0.03. The company had revenue of $4.13 billion for the quarter, compared to analyst estimates of $4.11 billion. Stryker had a net margin of 13.99% and a return on equity of 25.75%. Stryker’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.18 EPS. As a group, equities analysts anticipate that Stryker Co. will post 9.1 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a $0.575 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a $2.30 annualized dividend and a yield of 1.04%. Stryker’s payout ratio is 27.85%.

A number of analysts have recently commented on the stock. Morgan Stanley boosted their target price on shares of Stryker from $242.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Piper Jaffray Companies lowered shares of Stryker from an “overweight” rating to a “neutral” rating and set a $210.00 price target on the stock. in a research report on Tuesday, January 7th. Zacks Investment Research upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $215.00 price target on the stock in a research report on Thursday, November 28th. Cantor Fitzgerald restated a “neutral” rating on shares of Stryker in a research report on Wednesday, January 29th. Finally, BTIG Research restated a “buy” rating on shares of Stryker in a research report on Thursday, January 30th. Seven investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Stryker currently has an average rating of “Buy” and a consensus price target of $228.43.

In other Stryker news, COO Timothy J. Scannell sold 4,666 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $206.28, for a total value of $962,502.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 7.20% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: How Do You Make Money With Penny Stocks?

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.